Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer
Ricardo Hitt(Research Institute Hospital 12 de Octubre), H. Cortés-Funes(Centre Hospitalier René-Dubos), Alfredo Rizo(Hospital Universitario Miguel Servet), Vicente Valentí(Hospital Universitario Miguel Servet), Javier Martínez‐Trufero(Hospital Universitario Miguel Servet), Luis Paz‐Ares(Universidad Complutense de Madrid), C. Chaib(Hospital Universitario Miguel Servet), Francisco S. N. Lobo(Instituto Superior Técnico), Juan Luis Gomez Marti(Hospital Universitario Miguel Servet), Dolores Isla(Hospital Clínico Universitario Lozano Blesa), V. Javier Escrig(Hospital Universitario Miguel Servet), Antonio López–Pousa(Hospital de Sant Pau), Antonio Antón(Hospital Universitario Miguel Servet), Andrés Cervantes(Universitat de València), Cinta Pallarés(Hospital de Sant Pau), Pedro Pastor(Hospital Universitario Miguel Servet), M. Eugenia Vega(Hospital Universitario Miguel Servet), Miguel A. Sánchez(Hospital Universitario Miguel Servet), Joaquín Belón(Hospital Universitario Miguel Servet), Joan Carles(Vall d'Hebron Hospital Universitari)
Cited by 454
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
|New England Journal of Medicine|2008|3.7k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k